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Background Rheumatoid arthritis (RA) is an autoimmune disorder
that affects the small joints of the body. It is one of the leading causes
of chronic morbidity in high–income countries, but little is known
about the burden of this disease in low– and middle–income countries (LMIC).
Methods The aim of this study was to estimate the prevalence of RA
in six of the World Health Organization's (WHO) regions that harbour LMIC by identifying all relevant studies in those regions. To
accomplish this aim various bibliographic databases were searched:
PubMed, EMBASE, Global Health, LILACS and the Chinese databases CNKI and WanFang. Studies were selected based on pre–defined inclusion criteria, including a definition of RA based on the
1987 revision of the American College of Rheumatology (ACR) definition.
Results Meta–estimates of regional RA prevalence rates for countries
of low or middle income were 0.40% (95% CI: 0.23–0.57%) for
Southeast Asian, 0.37% (95% CI: 0.23–0.51%) for Eastern Mediterranean, 0.62% (95% CI: 0.47–0.77%) for European, 1.25% (95%
CI: 0.64–1.86%) for American and 0.42% (95% CI: 0.30–0.53%)
for Western Pacific regions. A formal meta–analysis could not be performed for the sub–Saharan African region due to limited data. Male
prevalence of RA in LMIC was 0.16% (95% CI: 0.11–0.20%) while
the prevalence in women reached 0.75% (95% CI: 0.60–0.90%).
This difference between males and females was statistically significant (P < 0.0001). The prevalence of RA did not differ significantly
between urban and rural settings (P = 0.353). These prevalence estimates represent 2.60 (95% CI: 1.85–3.34%) million male sufferers
and 12.21 (95% CI: 9.78–14.67%) million female sufferers in LMIC
in the year 2000, and 3.16 (95% CI: 2.25–4.05%) million affected
males and 14.87 (95% CI: 11.91–17.86%) million affected females
in LMIC in the year 2010.
Conclusion Given that majority of the world’s population resides in
LMIC, the number of affected people is substantial, with a projection
to increase in the coming years. Therefore, policy makers and health–
care providers need to plan to address a significant disease burden
both socially and economically.
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lation from a few studies is problematic given that there is
ample evidence that RA is a variable disease in time and place
[11]. Moreover, the burden of NCD has increased over the
past decade in LMIC, while it has decreased in high–income
countries [11]. RA also has a substantial economic impact,
which can be quantified as direct (cost of medication, hospital stay and visits, care–givers and helpers); indirect (loss
of productivity from absenteeism or early retirement); and
intangible costs that are measured by the impact on quality
of life [12,13]. In the United States, the direct cost of RA was
approximately US$ 13 500 per affected person per year, and
indirect costs could range between US$ 1000 and US$
33 000 per affected person per year [14]. However, not much
is known about costs in the developing world [13].

In recent years there has been a shift in diseases and health
related challenges that the world is facing. Non–communicable diseases (NCD) have emerged as the leading cause
of death worldwide, accounting for two–thirds of all deaths
and deaths are projected to increase in the coming years
[1]. Contrary to popular belief, these diseases are not limited to the developed world; they are increasingly prevalent
in low– and middle–income countries (LMIC), which are
facing the double burden of both communicable and non–
communicable diseases [2]. In LMIC, constrained health
care facilities, lack of resources and funds at individual and
national level lead to limited treatment and support for
NCD, which mainly affect the working age population with
a negative impact on household incomes and equity. The
high burden of NCD poses additional problems for LMIC,
creating a vicious cycle by worsening poverty that in turn
results in a further rise of NCD [1]. Acknowledgment of
the serious implications of the global burden of NCD has
led to an international response. The United Nations (UN)
High–level meeting on NCD in 2011 addressed these issues and has paved the way for tackling them, by providing guidance on how to strengthen national capacities to
address NCD and integrate prevention and control activities across sectors and at all levels of governance and
health–care provision in LMIC [1,2].

This paper aims to provide an estimate for the global and
regional burden of rheumatoid arthritis by systematically
reviewing relevant literature in both English databases and
those in other languages; to study the variation in the prevalence of rheumatoid arthritis by gender, region and setting
(urban/rural); and to discuss the significance of these prevalence estimates and their implications for public health
policy.

METHODS
Definition of population under study and
literature search

While there is wide recognition of the four main NCD with
a major contribution to the global burden – cardiovascular
diseases, cancers, diabetes mellitus and chronic respiratory
illnesses [2] – there are a large number of other NCD that
cause extensive morbidity, but are neglected as they do not
significantly contribute to mortality. One such disease is
rheumatoid arthritis (RA), the most common type of inflammatory musculoskeletal disorder [3,4], in which the
quality of life has been reported to be lower than in patients
suffering from most of the other NCD [5,6]. It is a chronic
systematic autoimmune inflammatory disease, characterised by a symmetrical persistent synovitis of the joints of
the hands, wrist, feet and knee resulting in tender swelling
of joints, pain, limitation in motion and morning stiffness.
Its systematic features include fatigue, generalised weakness, loss of weight and low grade fever [7]. As the disease
advances, irreversible tissue damage occurs, with destruction of bone and cartilage leading to joint deformity, muscle atrophy, and progression that may involve all joints of
the body [8]. For the purpose of clinical trials, RA is diagnosed using the American College of Rheumatology (ACR)
criteria, formerly known as the American Rheumatology
Association (ARA) criteria [7,9].

The World Bank database was referenced to compile a list
of all the LMIC in the world [15]. Thereafter, all LMIC were
grouped into regions in accordance to the World Health
Organization (WHO) regions [16]. WHO divides the world
into six regions; Southeast Asian Region (SEAR), Eastern
Mediterranean Region (EMR), Western Pacific Region
(WPR), Europe (EUR), The Americas (AMR) and Sub–Saharan Africa (AFR) [17–19]. A systematic literature search
was conducted separately for each region to find population based studies that documented the prevalence of RA.
Medline (1946 – July week 1, 2013), EMBASE (1976–
2013 week 26) and Global Health (GH) (1973 – 2013
week 26) were searched using the OVID search engine
(search terms available in Online Supplementary Document). Both Medical Subject Headings (MeSH terms) and
keywords were used in OVID. Other online databases such
as PubMed, Web of Knowledge (WoK) and databases selective to regions, such as LILACS for Latin America, CNKI
and Wan Fang for China, and IndMed for India, were also
thoroughly searched. PubMed was searched for all regions,
as it proved to be broader and more sensitive in picking up
studies. Grey literature was also searched for all low–middle income countries using SIGLE (OpenGrey), Google
Scholar and Global Health library. The search of grey literature resulted in 10 and 149 studies, respectively, none
of which were relevant to this analysis.

The prevalence of RA in the western world is 1–2% [10],
and is believed to be 1% worldwide [11]. However, this
global estimate is based on a few sporadic studies over different time periods, in a limited number of LMIC. Extrapo-
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Inclusion and exclusion criteria for study
selection

evant studies. Full texts of selected studies were analysed
and inclusion and exclusion criteria were applied. Data
from all relevant studies was extracted into an Excel spreadsheet, where sample size (age, sex–specific, mean age),
methodology, criteria used for diagnosing RA, study location (urban or rural) and prevalence rate were documented
for each study.

After the initial screen, inclusion and exclusion criteria
were applied to retain only the studies that were free of any
apparent bias. We included studies conducted in LMIC
from all WHO regions that were population based or community based, studies conducted after 1987 that used ARA/
ACR diagnostic criteria (see Table 1), focused on adult
populations (typically 15+ or 18+ years, with exclusion of
juvenile forms in the former studies) and reported the prevalence rate of RA. We excluded review articles with secondary data only (with the exception of sub–Saharan Africa,
where the amount of data was particularly scarce), hospital–based studies (for lack of representativeness of the general population), studies conducted prior to or during 1987
(for inconsistent case definition), studies on other types of
arthritis in adults, studies on juvenile forms of arthritis and
studies that used other diagnostic criteria to measure the
prevalence of RA in the population.

Adjustment of prevalence rates
Once the final set of studies was retained (Figure 1), crude
prevalence rates, sex–specific prevalence rates, urban and
rural prevalence rates and male–to–female ratio of RA cases were adjusted to the same measurement unit and expressed as a percentage. Data extracted from each study is
shown in the Online Supplementary Document. Checks
for internal consistency of the data were made and possible
significant correlations between prevalence rate and the
sample size, year of publication of the study, sex and residency were made.

We retained studies that clearly presented the method of
diagnosing RA, beginning with how the sample population
was recruited and evaluated, along with the criteria used
for diagnosis of RA. We expected that trained personnel or
specialists be involved in the field work, and we excluded
the studies where self–reporting was the primary method
of case ascertainment. Specialists (doctors, rheumatologists) needed to be involved in the next step of confirmation. Any study where there was no direct contact between
the assessors and sample population, such as telephone
surveys, were excluded. There is a high probability of misclassification and oversight of cases by untrained or inadequately trained personnel, or through indirect contact.

Statistical analyses
All statistical analyses are shown in the Online Supplementary Document. We first tested the distribution of the
reported prevalence of RA across all identified studies for
normality using the one–sample Kolmogorov-Smirnov test.
We concluded that the results did not indicate normal distribution, presumably because of substantial heterogeneity
in the included studies (Z = 1.831, P = 0.002). We then performed a meta–analysis of all identified studies in all LMIC
using the DerSimonian–Laird method, to determine the
“LMIC” prevalence rate (Online Supplementary Document).

Figure 1 summarises the process of study selection for all
six WHO regions. First, duplicates were excluded and titles
and abstracts of the retained papers were evaluated for rel-

We then displayed mean and median prevalences in each
of the six WHO regions (Figure 2). The Kruskal-Wallis

Table 1. The criteria of the American College of Rheumatology (ACR) established in 1987 to assist clinical diagnosis of rheumatoid
arthritis*
1. Morning stiffness
2. Arthritis of 3 or more joints
3. Arthritis of hand joints
4. Symmetric arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes

Morning stiffness in and around the joints, lasting at least 1 hour before maximal improvement
At least 3 joint areas simultaneously have had soft tissue swelling or fluid (not bony overgrowth alone) observed
by a physician. The 14 possible areas are right or left PIP, MCP, wrist, elbow, knee, ankle, and MTP joints
At least 1 area swollen (as defined above) in a wrist, MCP, or PIP joint
Simultaneous involvement of the same joint areas (as defined in 2) on both sides of the body (bilateral involvement of PIPs, MCPs, or MTPs is acceptable without absolute symmetry
Subcutaneous nodules, over bony prominences, or extensor surfaces, or in juxta–articular regions, observed by a
physician
Demonstration of abnormal amounts of serum rheumatoid factor by any method for which the result has been
positive in <5% of normal control subjects
Radiographic changes typical of rheumatoid arthritis on postero–anterior hand and wrist radiographs, which must
include erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints
(osteoarthritis changes alone do not qualify

PIP – proximal interphalangeal; MCP – metacarpophalangeal; MTP – metatarsophalangeal
*Four out of the seven criteria need to be met in order to establish the diagnosis of RA, with criteria 1–4 required to be present for at least 6 weeks. Patients with two clinical diagnoses are not excluded [9].
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Figure 1. Flowchart presenting the literature search and the process of study selection (WoK = Web of Knowledge;
G.H. = global health).

An important possible confounding effect was differences in
the mean age of the sample between the studies. This is because, although all samples were defined as “adult population” (usually 15 years of age or older), the relative contribution of elderly population varied in different countries
because of difference in sampling strategies and overall life
expectancy. We explored the association between the prevalence of RA and the mean age using linear correlation coefficients (Pearson, Kendall’s tau, and Spearman), and also the
generalised dependence measure mutual information to exclude the potential effect of age distribution on generalisability of the results (Online Supplementary Document).
Association between gender and prevalence of RA, where
a considerable difference between sexes was expected, was
explored using the paired samples t–test. We then conducted a gender–specific meta–analysis to estimate prevalence
and confidence intervals in men and women, using the
DerSimonian–Laird method. In addition, box–and–whiskers plots of regional prevalence by gender were also presented (Online Supplementary Document). We also examined the difference in prevalence of RA between urban
and rural populations. Since the RA prevalence is not normally distributed, we performed the non–parametric
Mann-Whitney U test to test the null–hypothesis.

Figure 2. The relationship between mean and median prevalence of rheumatoid arthritis in low and middle–income
countries in six WHO regions of the world.

one–way analysis of variance by ranks examined whether
samples originated from the same distribution. After this,
we conducted a series of region–specific meta–analyses to
estimate regional prevalence and confidence intervals, using the DerSimonian–Laird method (Online Supplementary Document).
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In our study, the majority of studies were from mainland
China, with additional studies from Taiwan and Hong
Kong. Mexico, Turkey, Iran, India, Pakistan, Philippines
and Russia were also represented through multiple studies.
The median year of publication was 2004, making the estimate useful for application to both the world population
in 2000 and 2010. Twenty–one studies used the ARA criteria, and all the remaining studies used the 1987 revised
ACR criteria. Some studies had multiple cohorts. Each cohort was recognised separately during analysis, so that the
final 48 studies resulted in 60 cohorts. In case of the African region, only two studies were found from the entire
region that fulfilled the criteria for inclusion. One of the
studies had a very small sample size and did not find a single case of RA, so it was excluded as uninformative. The
other study had a crude prevalence rate of 1%, but we felt
that it would be inadequate to base an entire regions' prevalence rate on a single study. Therefore, we decided to discard both of those studies and replace them by Bowman’s
systematic analysis in 2012 [20]. Bowman included all the
studies ever conducted in Africa in his estimate, irrespective of the year of study, and the prevalence rate from his
study was then applied to the population statistics of the
region in 2000 and 2010.

Figure 3. Regional median, minimum and maximum observed
value and inter–quartile range for the prevalence of rheumatoid
arthritis in low and middle–income countries in six WHO
regions of the world.

and the generalised dependence measure mutual information did not show an effect of mean age of the sample on
the reported prevalence of RA across the studies (P = 0.0599;
P > 0.05), implying that the differences in age structure of
samples in different studies were not the main determinant
of the observed heterogeneity.
An investigation into differences in prevalence by gender
using paired samples t–test indicated that the male and female RA prevalence differed significantly (P < 0.0001),
which was expected. We therefore conducted a separate
meta–analysis of the RA prevalence in LMIC countries for
men and women. Male prevalence was 0.16% (95% CI:
0.11–0.20%) (Figure 4) while the prevalence in women
was five times higher, amounting to 0.75% (95% CI: 0.60–
0.90%) (Figure 5). Data seemed to be less heterogeneous
for men (I2 = 49.6%) than for women (I2 = 83.7%).

When all studies were analysed in one large meta–analysis,
irrespective of their heterogeneity, this resulted in an
“LMIC” estimate for the prevalence of RA of 0.53% (95%
CI: 0.45–0.61%). Analysis of heterogeneity confirmed that
the data were highly heterogeneous (I2 = 96%) (Online
Supplementary Document). We then studied the mean
and median prevalence in each of the six WHO regions
(Figure 2) and presented box–and–whiskers plot of the
results from studies in each region (Figure 3). The KruskalWallis one–way analysis of variance by ranks test showed
that the prevalence in at least one of the WHO regions was
statistically different from the others (P = 0.029).

We also examined the difference in prevalence of RA between urban and rural populations, wherever information
was available to allow for comparison. Since we established
that the RA prevalence was not normally distributed, we
performed the non–parametric Mann-Whitney U test to
test the null hypothesis. The significance of the test was
P = 0.353, indicating that the prevalence in the urban and
rural settings do not differ significantly (Figure 6).

A series of region–specific meta–analyses were conducted
to estimate regional prevalence of RA. The meta–analysis
estimates of regional RA prevalence rates were 0.40% (95%
CI: 0.23–0.57%) for Southeast Asia, 0.37% (95% CI: 0.23–
0.51%) for Eastern Mediterranean, 0.62% (95% CI: 0.47–
0.77%) for European LMIC countries, 1.25% (95% CI:
0.64–1.86%) for American LMIC countries and 0.42%
(95% CI: 0.30–0.53%) for Western Pacific LMIC countries,
respectively. This analysis could not be performed for Africa due to limited data. The data sets were heterogeneous
in all the regions (I2 varied from 74.2% to 97.3%).

After all the previous analyses, a strategy was needed for
estimating the number of persons living with RA in LMIC
in the years 2000 and 2010. Possible approaches were: (i)
to apply the meta–analysis of the crude prevalence from all
identified studies to the total number of persons 15 years
or older in LMIC; (ii) to use the estimate of prevalence for
males and for females that resulted from the meta–analyses
of all studies that reported the rates separately by gender;

We then studied whether the mean age of the sample contributed to the observed prevalence rates. Linear correlation coefficients (Pearson, Kendall’s tau, and Spearman)
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Figure 4. Meta–analysis of
rheumatoid arthritis
prevalence in men, based on
all available information from
low and middle–income
countries in six WHO regions
of the world.

tion. However, the number of studies typically available for
different regions was simply too small to be sure whether
the observed differences between regions were real, or just
stochastic. The same applies to approach (iv). Therefore,
approach (ii) was used, because it accounted for the most
important confounding variable – gender – and because it
provided a lot of information for meta–analysis in each gender. This allowed an assumption that the rates considered
representative for all males and all females in LMIC were
more likely to be accurate than region–specific rates. Moreover, the observed heterogeneity of the underlying data was
the lowest in gender–specific meta–analysis across LMIC.

then, to apply those two estimates of prevalence to male
and female populations in LMIC; (iii) to use regional medians or the estimates based on regional meta–analysis and
apply them to the regional populations aged 15 years or
older; (iv) finally, to use sex–specific regional estimates and
apply it to male and female population aged 15 years or
older in respective regions.
Given the quantity and quality of the information that was
obtained through this systematic review, the most appropriate (and robust) approach was to use gender–specific
estimates of prevalence for the whole LMIC region and apply them to male and female populations in LMIC. There
are a number of reasons why other approaches were not
preferred and we will list them here. Although the quantity of information was the largest for the approach (i)
above, there is uncertainty in some studies over the composition of sample by gender, and whether it is representative of the underlying population. Given that gender is an
extremely important determinant of prevalence, the approach (i) would suffer from a possible confounding effect
of the gender composition of the sample. The strength of
approach (iii) was that it could account for regional varia-

June 2015 • Vol. 5 No. 1 • 010409

This gives an estimate of male prevalence of 0.156% (95%
CI: 0.11–0.20%) (Figure 4) that needs to be applied to the
male population aged 15 years or more in LMIC in 2000 and
2010. In females, the prevalence of 0.747% (95% CI: 0.60–
0.90%) is used (Figure 5). The UN Population Division's
estimates for the number of males aged 15 years or older in
LMIC in the year 2000 is 1.667 billion, and in the year 2010
it is 2.206 billion [17]. For women, the corresponding figures are 1.634 billion for the year 2000 and 1.991 billion in
2010 [17]. This translates into 2.60 (95% CI: 1.85–3.34%)
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Figure 5. Meta–analysis of
rheumatoid arthritis prevalence in women, based on all
available information from low
and middle–income countries
in six WHO regions of the
world.

million male sufferers and 12.21 (95% CI: 9.78–14.67%)
million female sufferers in the year 2000, and 3.16 (95% CI:
2.25–4.05%) million affected males and 14.87 (95% CI:
11.91–17.86%) million affected females in the year 2010 in
the countries of low and middle income.

DISCUSSION
We presented a robust estimate of the number of individuals suffering from RA in low and middle income countries
in 2000 and 2010. There have already been several attempts to estimate the prevalence of RA at the global, regional and national level and also in LMIC [10,11,14,18,19].
In comparison to previous estimates that presented both
higher and lower estimates than our study, our estimate is
based primarily on a substantial amount of evidence from
LMIC on sex–specific prevalence. We demonstrated that
gender is a principal determinant of RA in LMIC and that
age distribution of the population and being an urban
dweller do not contribute significantly to disease development. This is different from some other diseases, such as
dementia and cancer, where age seems to be the main de-

Figure 6. A scatterplot of observed prevalence rates of rheumatoid arthritis in six WHO regions based on urban or rural
residency of the examinees. No statistical differences were noted
(see Online Supplementary Document for further detail).
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ies towards a single plausible estimate. Besides three studies, in which we adjusted the estimate, all others determined
the prevalence rate using the same age cut–off (15 years or
older), again leading to comparable estimates underlying
each regional and the overall prevalence rate.

terminant, or schizophrenia, where being an urban dweller and family history seem to be the main driver of the disease occurrence [1,2]. Therefore, we believe that our
strategy for deriving the estimate was more appropriate
than used in some previous studies. Moreover, we provide
the full data set used to develop the estimates in Online
Supplementary Document and all our methods are transparent and replicable by other groups.

Although the best quality of epidemiological work on RA
in LMIC has been conducted by WHO–ILAR–COPCORD
[23], this program covers a limited number of countries
and this current review includes a larger number of studies
conducted elsewhere, by different researchers, leading to
wider coverage. Still, nearly all of the retained studies closely followed the three–step methodology set by WHO–
ILAR–COPCORD and used similar questionnaires, thereby
decreasing the methodological variability in the studies
[23]. The questionnaires were translated in local languages
and tested before the start of the studies in almost all cases.

Still, there are limitations in all estimates of the current
global burden of RA. The criteria of defining the disease
have changed over time and the estimates that don't take
this into account will be internally inconsistent. Moreover,
a mixture of studies, both hospital and population based
studies, could be considered, although the former will present the more severe end of disease spectrum and bias the
results. A major strength of our study is that it made use of
all literature available in all languages, including two major
Chinese databases and the database with grey literature.
We therefore believe that we are presenting the most advanced estimate of RA burden to date. However, limitations
are still large: there are very few data points (particularly in
Africa) and most LMIC countries do not have a single published epidemiological study. Moreover, most of the studies
used for this estimate are quite small and they are unlikely
to be nationally representative. Also, this study uses a wide
range of years to provide estimates for 2000 and 2010,
which is a limitation given that prevalence may be changing over time and that the time trend reported here arises
from demographic changes, rather than our understanding
of the epidemiological situation.

Nevertheless, variation remained even within the selected
studies that share the same three–step methodology. The
assessors at each stage were different between the studies.
In some studies, trained nurses administered the questionnaire, while in others this was done by trained volunteers
and students. At the second and third stage most studies
involved rheumatologists, but a handful of studies had general medical doctors or internists evaluate the potential cases. Moreover, among the studies conducted by COPCORD,
there was a slight regional variation in the questionnaire
used, given that it was modified over time, decreasing the
comparability of studies. Although the number of participants at each step is given, the reason of non–participation
is not stated in all studies. This may have led to non–respondent bias. Although this problem cannot be easily controlled, it still needs to be acknowledged, as there may be
a difference in characteristics of those who participate and
those who do not.

Our paper also aimed to explore whether other major covariates, besides gender, affect the frequency of the occurrence of RA. We were unable to demonstrate significant effects for either urban / rural living or age structure of the
study sample. Comparing all urban, rural and mixed studies amongst each other, we were unable to demonstrate significant differences between prevalence rates in urban or
rural areas. This is contrary to some previous reports that
suggested that the prevalence might be higher in urban areas [21]. Moreover, previous reports suggested that the
prevalence rate in LMIC is lower than in the developed
countries [22], which our study seems to generally support.

Research in developed countries does not seem to suggest
a growing trend in the prevalence of the disease. However,
the total number of cases grew considerably between 2000
and 2010 because the population of LMIC older than 15
years has grown in this period [24]. Even a slight increase
in the prevalence rate, eg, an additional prevalence of 0.1%,
would translate to an increment of 4 million affected persons. Given the fact that RA affects the working age population and most of the employment in these countries is
still for manual labour, it greatly decreases the productivity
of countries as a whole [25]. Additionally, the high costs of
treatment, borne by individuals themselves in the most
LMIC, counters other efforts to decrease poverty and improve living standards.

One of the major strengths of our study is that it involved
a systematic search of ten large databases, resulting in the
identification of 10 599 studies initially and 48 studies selected for inclusion. Native speakers translated studies in a
language other than English, specifically Chinese and
Spanish. This has greatly increased the pool of studies available for analysis, as it led to the inclusion of studies otherwise excluded due to language barriers. All of the studies
used the same definition to identify RA in patients: the
1987 revised ACR criteria (previously known as ARA criteria). This enabled comparison and convergence of stud-

June 2015 • Vol. 5 No. 1 • 010409

As RA is an important condition with significant morbidity and economic impact, it should be at the forefront in
health care policy. Despite this, RA as part of a larger group
of NCD receives less than 3% of annual development assistance for health to low and middle income countries.
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agencies already working towards generating information,
such as WHO–ILAR [23], should be undertaken and their
efforts should be supported. In Africa, the African League
of Associations of Rheumatology (AFLAR) already exists,
but little has been done in terms of research and surveillance of rheumatologic diseases [20]. Such associations
should be supported, encouraged and pressurised by governments to carry on more work in this area. The WHO–
ILAR–COPCORD program was developed to identify all
types of musculoskeletal disorders, and not specifically designed for rheumatoid arthritis nor as an epidemiological
study program [23]. Therefore, further research should be
specifically orientated towards rheumatoid arthritis, with
greater attention on the methodology. The lack of information from more than 100 LMIC countries should be addressed and gaps filled. Studies should also include age
groups of those with the disorder, thereby providing more
information on who bears the greatest burden and allowing age–standardised comparison. Simultaneously, information about risk factors should be obtained and incorporated in study designs.

The neglect of NCD on the global stage can be explained
not only by the gaps in estimates on burden of disease but
also from a lack of strategic communication about the urgency of the problem [26].
In this paper, estimates of RA morbidity aim to take a first
step in raising awareness of policy makers and health care
workers, as previously they have had to rely on the evidence that was generated mainly in the developed world.
The lack of specialists to diagnose and treat this condition
should also be addressed. In certain African nations there
is only one rheumatologist for the entire population [21].
Therefore, an increase in the number of specialists in this
area is urgently needed in LMIC [27]. As this takes time, the
existing doctors in the community should be offered specific education on RA, including newer treatment regimens
and the management of the associated comorbid conditions.
As most of the population resides in rural areas, incorporating identification and treatment of the disease in community health care system is crucial to reach all those in need
of diagnosis and treatment. Funding should be targeted at
increasing efficacy of treatments in LMIC. Efforts should be
made to increase the availability of treatment – both anti–
inflammatories and the newer biological agents that have
proven to be greatly beneficial – at affordable costs. The
newer biological agents are very expensive and it is unlikely that many LMIC could afford to supply them [25]. Moreover, RA is associated with an increased risk of other diseases (such as cardiovascular diseases) and the management
of these comorbid conditions is also important. All doctors
should be made aware of treatment protocols already in use
by high–income countries with emphasis on early treatment, to slow disease progression and elimination of pain.
This should lead to improvements in quality of life and decrease the occurrence of co–morbid conditions, such as depression. The set–up of supportive treatment, such as physiotherapy, should be encouraged [11–18].

The estimates presented in this paper provide a building
block for future epidemiological studies by suggesting the
way forward in disease assessment in LMIC context and
the methodology that could be deployed. It could also be
used to create awareness among health–care workers and
education of people about the disease and encourage
health–seeking behaviour for provision of available treatment, which can decrease the burden associated with disability and bring about a decrease in morbidity. It is also
noteworthy to point out the reoccurring theme of lack of
data from the poorest countries. Policy makers from these
countries should show more dedication and step up their
efforts towards research in the health care sector, as generating information about the burden of disease is the first
step in decreasing its prevalence.

Infrastructure for research in areas where it is currently unavailable should be set up. Allegiance with international
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